Optimer's fidaxomicin is as effective as Vancocin in late-stage study

02/4/2010 | Reuters

Optimer Pharmaceuticals' fidaxomicin was as effective as standard therapy Vancocin in treating Clostridium difficile infection in a second Phase III trial, the company announced. The antibiotic also demonstrated a higher cure rate without recurrence and a lower recurrence rate compared with Vancocin in the four-week treatment period, according to the study.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA